

Table of Contents

Summary	i
Acknowledgments	v
List of Abbreviations	viii
Introduction	1
1.1 Malaria – An overview	2
1.1.1 <i>Plasmodium</i> spp. life cycle	2
1.1.2 Epidemiology and burden of malaria	5
1.1.3 <i>Plasmodium malariae</i> and <i>ovale</i> spp. - the neglected malaria parasites	7
1.1.4 Malaria control methods	8
1.1.5 Malaria diagnosis	10
1.2 Host immune response and development of vaccines	14
1.2.1 Naturally acquired immunity to malaria	14
1.2.2 Immunological correlates of vaccine efficacy	15
1.2.3 Malaria vaccines	15
1.2.4 Whole sporozoite vaccines	19
1.3 Controlled Human Malaria Infections (CHMI)	21
1.3.1 CHMI: One hundred years of experience	21
1.3.2 An accelerator for vaccine and drug development?	22
1.3.3 CHMI as a tool to study host and parasite immunobiology	23
1.3.4 Monitoring of parasitaemia during CHMI	24
1.4 Aims of this thesis	25

Molecular monitoring of asexual blood stage parasites at the individual level	27
2.1 PISPZ Vaccine safety, immunogenicity and efficacy against CHMI in Tanzanian and Equato-Guinean volunteers	28
2.2 Controlled Human Malaria Infections in Tanzania and Equatorial Guinea: The impact of malaria pre-exposure on diagnosis and multiplication rate of <i>P. falciparum</i> parasites	68
Development of high-throughput, field deployable tools for malaria surveillance	101
3.1 A multiplex qPCR approach for detection of <i>pfhrp2</i> and <i>pfhrp3</i> gene deletions in multiple strain infections of <i>Plasmodium falciparum</i>	104
3.2 High Throughput Extraction and Analysis of Nucleic Acids from Rapid Diagnostic Tests for Molecular Surveillance of Malaria	136
3.3 ELIMU-MDX: A Web-Based, Open-Source Platform for Storage, Management and Analysis of Diagnostic qPCR Data	177
Active surveillance of <i>P. malariae</i> and <i>P. ovale</i> spp. infections in Tanzania and Equatorial Guinea	196
4.1 Molecular monitoring of the diversity of human pathogenic malaria species in blood donations on Bioko Island, Equatorial Guinea	198
4.2 Two cases of long-lasting, sub-microscopic <i>Plasmodium malariae</i> infections in adults from Coastal Tanzania	209
Discussion	217
5.1 Evaluation of the PISPZ Vaccine in two different malaria pre-exposed populations	218
5.2 The use of CHMI for assessing vaccine efficacy	219
5.3 The impact of naturally acquired immunity on vaccination and CHMI	221
5.4 Development and implementation of tools for molecular malaria surveillance	223
Conclusion and future directions	226
References	230
Appendix	250